Nick Valiante

Company: Innovac Therapeutics

Job title: Co-Founder & Chief Scientific Officer

Seminars:

A Phase Ia Study to Assess the Safety, Tolerability & Immunogenicity of a Personalized Cancer Vaccine (InnoPCV/INV002) in Patients With Advanced Solid Tumors 12:30 pm

• Overview of Innovac’s approach to optimizing every step of the PCV value chain • Current regulatory environment for mRNA/LNP personalized cancer vaccine entering Phase 1 clinical trials • INV002 human safety and tolerability results INV002 neoantigen-specific T cell induction and patient biomarker resultsRead more

day: Conference Day Two